Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium t…
发布时间:2023-07-17浏览数:773
In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76…
发布时间:2021-05-06浏览数:633
Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life.
发布时间:2021-02-14浏览数:758
These studies have profound implications for the development of therapeutic Aβ antibodies for Alzheimer's disease.
发布时间:2012-01-06浏览数:737
A beta N3(pE) production and retention may play an early and critical role in senile plaque formation.
发布时间:1995-02-01浏览数:654
横切线®为注册商标
Copyright 2020 横切线®药研苑 备案号:粤ICP备18041379号-3